Evidence map›Paper›PMID 22002489›Full record

GuidelineBone marrow transplantation2012

Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.

J A Snowden, R Saccardi, M Allez, S Ardizzone, R Arnold, R Cervera, C Denton, C Hawkey, M Labopin, G Mancardi and 10 more

Registry-linked trialOpen access · hybridAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Bone marrow transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03113162 (Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation), which is not on this map. Cited by 134 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 7 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03113162 phase1unknown statusnot on this mapstarted 2015, after this paper: background citation

Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis

TypeinterventionalSponsorMakati Medical CenterRan2015 to 2022Enrolled15ConditionsMultiple SclerosisArmsAutologous Hematopoietic Stem Cell, BEAM Regimen
3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 7 syntheses or guidelines pooled it, 320 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Stem cell transplantation for systemic sclerosis.The Cochrane database of systematic reviews · 2022
    Pooled it
  5. Guideline
  6. Guideline
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 8 countries.

J A SnowdenDepartment of Haematology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK. john.snowden@sth.nhs.uk
R Saccardi
M Allez
S Ardizzone
R Arnold
R Cervera
C Denton
C Hawkey
M Labopin
G Mancardi
R Martin
J J Moore
J Passweg
C Peters
M Rabusin
M Rovira
J M van Laar
D Farge
EBMT Autoimmune Disease Working Party (ADWP)
Paediatric Diseases Working Party (PDWP)
Inserm · FRHospital Clínic de Barcelona · ESIRCCS Materno Infantile Burlo Garofolo · ITUniversity Hospital of Basel · CHUniversity of Nottingham · GBLuigi Sacco Hospital · ITRoyal Free London NHS Foundation Trust · GBSheffield Teaching Hospitals NHS Foundation Trust · GBSorbonne Université · FRSt Vincent's Hospital Sydney · AUUniversity of Genoa · ITUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.

Indexed as

Autoimmune DiseasesClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicEuropean UnionFemaleHematopoietic Stem Cell TransplantationHumansMaleRisk FactorsSafetySeverity of Illness Index

Identifiers

PMID22002489
PMCPMC3371413
OpenAlexW2118649180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.